Showing results (61-70 of 1,984) with videos related to
Sort By:
Pageof 199
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F ThallCurrent Opinion in Oncology|June 6, 2008
Bayesian designs to account for patient heterogeneity in phase II clinical trialsPeter F Thall, J Kyle WathenJournal of the Royal Statistical Society. Series C, Applied Statistics|May 21, 2019
Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event timesJuhee Lee, Peter F Thall, Katy RezvaniClinical Trials (London, England)|December 19, 2023
Risk-benefit trade-offs and precision utilities in phase I-II clinical trialsPavlos Msaouel, Juhee Lee, Peter F ThallBiometrics|June 6, 2018
Bayesian optimal interval design with multiple toxicity constraintsRuitao LinApplied Stochastic Models in Business and Industry|December 5, 2017
Clinical Trial Design as a Decision ProblemPeter Müller, Yanxun Xu, Peter F ThallStatistics & Probability Letters|July 30, 2014
A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity ConstraintLu Wang, Jincheng Shen, Peter F ThallBayesian Analysis|November 1, 2013
Prior Effective Sample Size in Conditionally Independent Hierarchical ModelsSatoshi Morita, Peter F Thall, Peter MüllerCancers|July 2, 2021
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical OutcomesPavlos Msaouel, Juhee Lee, Peter F ThallStatistics in Medicine|April 8, 2020
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and deathJuhee Lee, Peter F Thall, Pavlos MsaouelPageof 199